PCSA

SEC source: 0000897069-26-001602 · form4.xml · derivative · entry 4

Ng George K · CIK 0001638744 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,624

Underlying: Common Stock · 1,600 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Distribution of time-based service award.

F1 · derivative.expiration_date: Distribution of time-based service award.

F3 · balance_after: Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025.

SEC source: 0000897069-26-001602 · form4.xml · nonDerivative · entry 1

Ng George K · CIK 0001638744 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,092

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Distribution of time-based service award.

SEC source: 0001575202-26-000011 · form4-07312026_010752.xml · derivative · entry 2

GUJRATHI SHEILA · CIK 0001575202 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By SilverArc Private Fund I, L.P.

Disclosed balance after: 12,311.279

Underlying: Common Stock · 12,311.279 shares

Expires not disclosed

F1 · derivative.exercise_price: Each share of Series A Non-Voting Convertible Preferred Stock (the "Series A Preferred Stock") is convertible into 1,000 shares of common stock of Processa Pharmaceuticals, Inc. (the "Company"). The Preferred Stock has no expiration date.

F2 · kind: Received in exchange for shares of common stock of Vidya Therapeutics, Inc. ("Vidya") pursuant to an Agreement and Plan of Merger, dated July 28, 2026 (the "Merger Agreement"), by and among the Company, Vidya, Venus Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Company ("Merger Sub I"), Venus Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company ("Merger Sub II"), at an exchange ratio of 162.811 shares of Vidya common stock for each share of Company common stock.

F3 · kind: Under the terms of the Merger Agreement, on July 28, 2026, Merger Sub I merged with and into Vidya, with Vidya surviving the first merger as a wholly owned subsidiary of the Company, and immediately following the first merger, Vidya merged with and into Merger Sub II, with Merger Sub II surviving the second merger as a wholly owned subsidiary of the Company (such mergers, the "Merger"). Upon the closing of the Merger, shares of outstanding common stock of Vidya converted into the right to receive shares of the Company's Series A Preferred Stock in accordance with the Merger Agreement. Subject to certain conditions set forth in the Certificate of Designation of Preferences, Rights and Limitations of the Series A Preferred Stock, each share of Series A Preferred Stock is convertible into 1,000 shares of the Company's common stock.

F2 · price: Received in exchange for shares of common stock of Vidya Therapeutics, Inc. ("Vidya") pursuant to an Agreement and Plan of Merger, dated July 28, 2026 (the "Merger Agreement"), by and among the Company, Vidya, Venus Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Company ("Merger Sub I"), Venus Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company ("Merger Sub II"), at an exchange ratio of 162.811 shares of Vidya common stock for each share of Company common stock.

F3 · price: Under the terms of the Merger Agreement, on July 28, 2026, Merger Sub I merged with and into Vidya, with Vidya surviving the first merger as a wholly owned subsidiary of the Company, and immediately following the first merger, Vidya merged with and into Merger Sub II, with Merger Sub II surviving the second merger as a wholly owned subsidiary of the Company (such mergers, the "Merger"). Upon the closing of the Merger, shares of outstanding common stock of Vidya converted into the right to receive shares of the Company's Series A Preferred Stock in accordance with the Merger Agreement. Subject to certain conditions set forth in the Certificate of Designation of Preferences, Rights and Limitations of the Series A Preferred Stock, each share of Series A Preferred Stock is convertible into 1,000 shares of the Company's common stock.

F1 · derivative.exercise_date: Each share of Series A Non-Voting Convertible Preferred Stock (the "Series A Preferred Stock") is convertible into 1,000 shares of common stock of Processa Pharmaceuticals, Inc. (the "Company"). The Preferred Stock has no expiration date.

F1 · derivative.expiration_date: Each share of Series A Non-Voting Convertible Preferred Stock (the "Series A Preferred Stock") is convertible into 1,000 shares of common stock of Processa Pharmaceuticals, Inc. (the "Company"). The Preferred Stock has no expiration date.

F4 · ownership.nature: The Reporting Person is Co-Portfolio Manager and has membership interest in SilverArc Private Capital I, LLC (Ultimate General Partner), SilverArc Private Capital I, LP (General Partner), and SilverArc Private Capital Management I, LP (Management Company) for SilverArc Private Fund I, L.P. The Reporting Person may not be deemed to have voting or investment power over the shares held of record by SilverArc Private Fund I, LP. The Reporting Person disclaims beneficial ownership of such securities held of record by SilverArc Private Fund I, L.P., except to the extent of any pecuniary interest therein.

SEC source: 0001575202-26-000011 · form4-07312026_010752.xml · derivative · entry 1

GUJRATHI SHEILA · CIK 0001575202 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,811.877

Underlying: Common Stock · 70,811.877 shares

Expires not disclosed

F1 · derivative.exercise_price: Each share of Series A Non-Voting Convertible Preferred Stock (the "Series A Preferred Stock") is convertible into 1,000 shares of common stock of Processa Pharmaceuticals, Inc. (the "Company"). The Preferred Stock has no expiration date.

F2 · kind: Received in exchange for shares of common stock of Vidya Therapeutics, Inc. ("Vidya") pursuant to an Agreement and Plan of Merger, dated July 28, 2026 (the "Merger Agreement"), by and among the Company, Vidya, Venus Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Company ("Merger Sub I"), Venus Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company ("Merger Sub II"), at an exchange ratio of 162.811 shares of Vidya common stock for each share of Company common stock.

F3 · kind: Under the terms of the Merger Agreement, on July 28, 2026, Merger Sub I merged with and into Vidya, with Vidya surviving the first merger as a wholly owned subsidiary of the Company, and immediately following the first merger, Vidya merged with and into Merger Sub II, with Merger Sub II surviving the second merger as a wholly owned subsidiary of the Company (such mergers, the "Merger"). Upon the closing of the Merger, shares of outstanding common stock of Vidya converted into the right to receive shares of the Company's Series A Preferred Stock in accordance with the Merger Agreement. Subject to certain conditions set forth in the Certificate of Designation of Preferences, Rights and Limitations of the Series A Preferred Stock, each share of Series A Preferred Stock is convertible into 1,000 shares of the Company's common stock.

F2 · price: Received in exchange for shares of common stock of Vidya Therapeutics, Inc. ("Vidya") pursuant to an Agreement and Plan of Merger, dated July 28, 2026 (the "Merger Agreement"), by and among the Company, Vidya, Venus Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Company ("Merger Sub I"), Venus Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company ("Merger Sub II"), at an exchange ratio of 162.811 shares of Vidya common stock for each share of Company common stock.

F3 · price: Under the terms of the Merger Agreement, on July 28, 2026, Merger Sub I merged with and into Vidya, with Vidya surviving the first merger as a wholly owned subsidiary of the Company, and immediately following the first merger, Vidya merged with and into Merger Sub II, with Merger Sub II surviving the second merger as a wholly owned subsidiary of the Company (such mergers, the "Merger"). Upon the closing of the Merger, shares of outstanding common stock of Vidya converted into the right to receive shares of the Company's Series A Preferred Stock in accordance with the Merger Agreement. Subject to certain conditions set forth in the Certificate of Designation of Preferences, Rights and Limitations of the Series A Preferred Stock, each share of Series A Preferred Stock is convertible into 1,000 shares of the Company's common stock.

F1 · derivative.exercise_date: Each share of Series A Non-Voting Convertible Preferred Stock (the "Series A Preferred Stock") is convertible into 1,000 shares of common stock of Processa Pharmaceuticals, Inc. (the "Company"). The Preferred Stock has no expiration date.

F1 · derivative.expiration_date: Each share of Series A Non-Voting Convertible Preferred Stock (the "Series A Preferred Stock") is convertible into 1,000 shares of common stock of Processa Pharmaceuticals, Inc. (the "Company"). The Preferred Stock has no expiration date.

SEC source: 0000897069-26-001556 · form4.xml · derivative · entry 2

Pannu Geraldine · CIK 0001817209 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,749

Underlying: Common Stock · 33,500 shares

Expires not disclosed

F1 · shares: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death.

F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death.

F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death.

F3 · balance_after: Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025.

SEC source: 0000897069-26-001548 · form4.xml · derivative · entry 3

Guy Wendy · CIK 0001799360 · Chief Administrative Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,669

Underlying: Common Stock · 9,450 shares

Expires not disclosed

F1 · shares: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death.

F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death.

F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death.

F3 · balance_after: Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025.

SEC source: 0000897069-26-001550 · form4.xml · derivative · entry 3

Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,389

Underlying: Common Stock · 8,450 shares

Expires not disclosed

F1 · shares: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death.

F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death.

F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death.

F3 · balance_after: Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025.

SEC source: 0000897069-26-001546 · form4.xml · derivative · entry 2

Baluch Khoso · CIK 0001686223 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,749

Underlying: Common Stock · 33,500 shares

Expires not disclosed

F1 · shares: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death.

F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death.

F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death.

F3 · balance_after: Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025.

SEC source: 0000897069-26-001554 · form4.xml · derivative · entry 4

Ng George K · CIK 0001638744 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,224

Underlying: Common Stock · 9,384 shares

Expires not disclosed

F1 · shares: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death.

F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death.

F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death.

F3 · balance_after: Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025.

SEC source: 0000897069-26-001558 · form4.xml · derivative · entry 2

SKIBSTED RUSSELL · CIK 0001308105 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,323

Underlying: Common Stock · 11,883 shares

Expires not disclosed

F1 · shares: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death.

F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death.

F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death.

F3 · balance_after: Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025.

SEC source: 0000897069-26-001560 · form4.xml · derivative · entry 4

Yorke Justin W · CIK 0001361896 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,749

Underlying: Common Stock · 33,500 shares

Expires not disclosed

F1 · shares: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death.

F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death.

F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death.

F3 · balance_after: Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025.

SEC source: 0000897069-26-001552 · form4.xml · derivative · entry 2

Neal James R · CIK 0001600865 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,470

Underlying: Common Stock · 62,221 shares

Expires not disclosed

F1 · shares: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death.

F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death.

F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death.

F3 · balance_after: Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025.

SEC source: 0000897069-26-001480 · form4.xml · nonDerivative · entry 1

Ng George K · CIK 0001638744 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,492

SEC source: 0000897069-26-001484 · form4.xml · nonDerivative · entry 1

Guy Wendy · CIK 0001799360 · Chief Administrative Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,394

SEC source: 0000897069-26-001482 · form4.xml · nonDerivative · entry 1

Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,113

SEC source: 0000897069-26-001478 · form4.xml · nonDerivative · entry 1

SKIBSTED RUSSELL · CIK 0001308105 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,689

SEC source: 0000897069-26-001476 · form4.xml · nonDerivative · entry 1

Young David · CIK 0001378166 · Director · Pres. Research & Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,729

SEC source: 0000897069-26-001470 · form4.xml · derivative · entry 2

Pannu Geraldine · CIK 0001817209 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,249

Underlying: Common Stock · 203 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Distribution of time-based service award.

F1 · derivative.expiration_date: Distribution of time-based service award.

SEC source: 0000897069-26-001470 · form4.xml · nonDerivative · entry 1

Pannu Geraldine · CIK 0001817209 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,391

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Distribution of time-based service award.

SEC source: 0000897069-26-001466 · form4.xml · derivative · entry 2

Baluch Khoso · CIK 0001686223 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,249

Underlying: Common Stock · 203 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Distribution of time-based service award.

F1 · derivative.expiration_date: Distribution of time-based service award.

SEC source: 0000897069-26-001466 · form4.xml · nonDerivative · entry 1

Baluch Khoso · CIK 0001686223 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,528

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Distribution of time-based service award.

SEC source: 0000897069-26-001472 · form4.xml · derivative · entry 4

Yorke Justin W · CIK 0001361896 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,249

Underlying: Common Stock · 203 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Distribution of time-based service award.

F1 · derivative.expiration_date: Distribution of time-based service award.

SEC source: 0000897069-26-001472 · form4.xml · nonDerivative · entry 1

Yorke Justin W · CIK 0001361896 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 353

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Distribution of time-based service award.

SEC source: 0000897069-26-001468 · form4.xml · derivative · entry 2

Neal James R · CIK 0001600865 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,249

Underlying: Common Stock · 203 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Distribution of time-based service award.

F1 · derivative.expiration_date: Distribution of time-based service award.

SEC source: 0000897069-26-001468 · form4.xml · nonDerivative · entry 1

Neal James R · CIK 0001600865 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,021

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Distribution of time-based service award.

SEC source: 0000897069-26-001406 · form4.xml · nonDerivative · entry 1

Guy Wendy · CIK 0001799360 · Chief Administrative Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,958

SEC source: 0000897069-26-001408 · form4.xml · nonDerivative · entry 1

Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,007

SEC source: 0000897069-26-001410 · form4.xml · nonDerivative · entry 1

Ng George K · CIK 0001638744 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,435

SEC source: 0000897069-26-001412 · form4.xml · nonDerivative · entry 1

SKIBSTED RUSSELL · CIK 0001308105 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,412

SEC source: 0000897069-26-001414 · form4.xml · nonDerivative · entry 1

Young David · CIK 0001378166 · Director · Pres. Research & Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,198

SEC source: 0000897069-26-001287 · form4.xml · nonDerivative · entry 1

Guy Wendy · CIK 0001799360 · Chief Administrative Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,840

SEC source: 0000897069-26-001289 · form4.xml · nonDerivative · entry 1

Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,176

SEC source: 0000897069-26-001291 · form4.xml · nonDerivative · entry 1

Ng George K · CIK 0001638744 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,970

SEC source: 0000897069-26-001293 · form4.xml · nonDerivative · entry 1

SKIBSTED RUSSELL · CIK 0001308105 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,758

SEC source: 0000897069-26-001295 · form4.xml · nonDerivative · entry 1

Young David · CIK 0001378166 · Director · Pres. Research & Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,131

SEC source: 0000897069-26-001176 · form4.xml · nonDerivative · entry 1

Guy Wendy · CIK 0001799360 · Chief Administrative Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,011

F1 · balance_after: Shares adjusted to correct immaterial errors made on the Form 4 filed on May 1, 2026. The corrected price per share for the purchase made on April 30, 2026 is $2.71, not $2.69, which reduces the amount purchased on April 30, 2026 by 13 shares.

SEC source: 0000897069-26-001182 · form4.xml · nonDerivative · entry 1

Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,594

F1 · balance_after: Shares adjusted to correct immaterial errors made on the Form 4 filed on May 1, 2026. The corrected price per share for the purchase made on April 30, 2026 is $2.71, not $2.69, which reduces the amount purchased on April 30, 2026 by 11 shares.

SEC source: 0000897069-26-001186 · form4.xml · nonDerivative · entry 1

Ng George K · CIK 0001638744 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,841

F1 · balance_after: Shares adjusted to correct immaterial errors made on the Form 4 filed on May 1, 2026. The corrected price per share for the purchase made on April 30, 2026 is $2.71, not $2.69, which reduces the amount purchased on April 30, 2026 by 15 shares.

SEC source: 0000897069-26-001171 · form4.xml · nonDerivative · entry 1

SKIBSTED RUSSELL · CIK 0001308105 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,466

F1 · balance_after: Shares adjusted to correct immaterial errors made on the Form 4 filed on May 1, 2026. The corrected price per share for the purchase made on April 30, 2026 is $2.71, not $2.69, which reduces the amount purchased on April 30, 2026 by 16 shares.

SEC source: 0000897069-26-001184 · form4.xml · nonDerivative · entry 1

Young David · CIK 0001378166 · Director · Pres. Research & Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,345

F1 · balance_after: Shares adjusted to correct immaterial errors made on the Form 4 filed on May 1, 2026. The corrected price per share for the purchase made on April 30, 2026 is $2.71, not $2.69, which reduces the amount purchased on April 30, 2026 by 13 shares.

SEC source: 0000897069-26-001002 · form4.xml · nonDerivative · entry 1

Guy Wendy · CIK 0001799360 · Chief Administrative Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,441

SEC source: 0000897069-26-001004 · form4.xml · nonDerivative · entry 1

Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,236

SEC source: 0000897069-26-001000 · form4.xml · nonDerivative · entry 1

Bigora Sian · CIK 0001799365 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,496

SEC source: 0000897069-26-001006 · form4.xml · nonDerivative · entry 1

Ng George K · CIK 0001638744 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,013

SEC source: 0000897069-26-001008 · form4.xml · nonDerivative · entry 1

SKIBSTED RUSSELL · CIK 0001308105 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,498

SEC source: 0000897069-26-001010 · form4.xml · nonDerivative · entry 1

Young David · CIK 0001378166 · Director · Pres. Research & Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,813

SEC source: 0000897069-26-001154 · form4a.xml · nonDerivative · entry 1

Bigora Sian · CIK 0001799365 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,481

F1 · shares: Shares adjusted to correct immaterial errors.

F1 · price: Shares adjusted to correct immaterial errors.

F1 · balance_after: Shares adjusted to correct immaterial errors.

SEC source: 0000897069-26-000906 · form4.xml · nonDerivative · entry 1

Guy Wendy · CIK 0001799360 · Chief Administrative Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,693

SEC source: 0000897069-26-000908 · form4.xml · nonDerivative · entry 1

Lin Patrick · CIK 0001799363 · Chief Business - Strategy Off

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,725

SEC source: 0000897069-26-000904 · form4.xml · nonDerivative · entry 1

Bigora Sian · CIK 0001799365 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,510